RG Paediatric Psychopharmacology
Registrar, Head of the Research Group
Phone: +49 621 1703-4522
Fax: +49 621 1703-4525
Main Medical Building, 1st Floor, Room 129
Ruth Berg, E-Mail, Phone: +49 621 1703-4541, Fax: +49 621 1703-4545
Main Medical Building, 1st Floor, Room 146
The research group represents this relatively new field within children and adolescent psychiatry (CAP) both in teaching and research. With respect to conduct of clinical trials with children and adolescents, it is also involved in the clinical work of the department of CAP. The main objectives of the research group are fostering of clinical trials in paediatric psychopharmacology with sponsoring from both public funding agencies and the pharmaceutical industry, development of international trial site networks for multi-centre trials and collaboration with adjacent departments in translational research projects.
Main focus of the research group is the investigation of efficacy and safety/tolerability of psychopharmacological interventions in children and adolescents.
Since the formation of the working group in 2007, trials in patients with, e.g., attention-deficit /hyperactivity disorder, autism spectrum disorder, major depression/bipolar disorder, schizophrenia, conduct disorder, Tourette syndrome/tic disorder were established, continued or concluded. Several trials were conducted in collaboration with the pharmaceutical industry and members of the department were entrusted with leadership responsibilities on national, European, and transcontinental levels.
The research group participated in the EU-funded (FP 7) projects ADDUCE (long-term safety of methylphenidate), PERS (risperidone in conduct disorder), STOP (medication-related suicidality) and TACTICS (glutamatergic treatment approaches in ASD and OCD) and the German health ministry funded (Federal Ministry of Education and Research) project DEMIJO (St.-John's-wort in depressive disorders).
Currently, the research group participates in the EU-funded (H2020) projects Eat2beNice (Contribution of nutrition and lifestyle to mental health) and PRIME (Effects of prevention and remediation of insulin multimorbidity to different somatic and psychiatric diseases). Furthermore, the research group is engaged in several trials under sponsorship of pharmaceutical companies.
In 2019, the research group received the research award of the German Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie for research achievements in the field of medication adherence in mentally ill adolescents.
More Informationen to the RG Paediatric Psychopharmakology
Zentralinstitut für Seelische Gesundheit (ZI) - https://www.zi-mannheim.de